Southwest Institute for Research on Women, College of Social and Behavioral Sciences University of Arizona, Tucson, Arizona, United States of America.
Family and Community Medicine, College of Medicine, University of Arizona, Tucson, Arizona, United States of America.
PLoS One. 2022 Oct 25;17(10):e0274094. doi: 10.1371/journal.pone.0274094. eCollection 2022.
To understand patient experience of federal regulatory changes governing methadone and buprenorphine (MOUD) access in Arizona during the COVID-19 pandemic.
This community-based participatory and action research study involved one-hour, audio-recorded field interviews conducted with 131 people who used methadone and/or buprenorphine to address opioid use disorder at some point during COVID (January 1, 2020- March 31, 2021) in Arizona. Transcribed data were analyzed using a priori codes focused on federally recommended flexibilities governing MOUD access. Data were quantitated to investigate associations with COVID risk and services access.
Telehealth was reported by 71.0% of participants, but the majority were required to come to the clinic to attend video appointments with an offsite provider. Risk for severe COVID outcomes was reported by 40.5% of the sample. Thirty-eight percent of the sample and 39.7% of methadone patients were required to be at the clinic daily to get medication and 47.6% were at high risk for COVID severe outcomes. About half (54.2%) of methadone patients indicated that some form of multi-day take home dosing was offered at their clinic, and 45.8% were offered an extra day or two of multi-day doses; but no participants received the federally allowed 14- or 28-day methadone take-home doses for unstable and stable patients respectively. All participants expressed that daily clinic visits interrupted their work and home lives and desired more take-home dosing and home delivery options.
MOUD patients in Arizona were not offered many of the federally allowed flexibilities for access that were designed to reduce their need to be at the clinic. To understand the impact of these recommended treatment changes in Arizona, and other states where they were not well implemented, federal and state regulators must mandate these changes and support MOUD providers to implement them.
了解在 COVID-19 大流行期间,亚利桑那州患者对管理美沙酮和丁丙诺啡(MOUD)准入的联邦监管变化的体验。
本社区参与式和行动研究包括对 131 名在 COVID 期间(2020 年 1 月 1 日至 2021 年 3 月 31 日)曾使用美沙酮和/或丁丙诺啡治疗阿片类药物使用障碍的人进行了为时一小时的录音现场访谈。使用预先设定的代码对转录数据进行分析,这些代码重点关注联邦推荐的 MOUD 准入灵活性。对数据进行定量分析,以调查与 COVID 风险和服务获取的关联。
71.0%的参与者报告了远程医疗,但大多数人都需要到诊所参加与远程提供者的视频预约。该样本中有 40.5%报告了发生严重 COVID 后果的风险。该样本的 38%和 39.7%的美沙酮患者需要每天到诊所取药,47.6%的人有发生 COVID 严重后果的高风险。大约一半(54.2%)的美沙酮患者表示,他们的诊所提供某种形式的多日带药回家方案,45.8%的患者提供额外的一到两天多日剂量;但没有参与者获得联邦允许的不稳定和稳定患者分别 14 天或 28 天的美沙酮带药回家剂量。所有参与者都表示,每天的诊所就诊打断了他们的工作和家庭生活,希望获得更多的带药回家和上门送药的选择。
亚利桑那州的 MOUD 患者并未获得许多为减少其到诊所就诊需求而设计的联邦准入灵活性。为了了解这些推荐的治疗方案变化在亚利桑那州和其他实施不佳的州的影响,联邦和州监管机构必须强制实施这些变化,并支持 MOUD 提供者实施这些变化。